Shares of ReNeuron Group Plc (LON: RENE) today surged 10.2% after the company announced that it had started extended phase IIa trials of its hRPC cell therapy for retinitis pigmentosa, a degenerative eye condition.
The company which specialises in stem-cell research today announced that it had started dosing procedures within the US and that the expanded phase IIa trial will include at least nine people who will receive higher doses of the hRPC cell therapy.
Ten patients are already participating in the study, which will raise the total number to nineteen patients, distributed across the UK and America. Further results will be published in the next 12 months.
WELCOME BONUS
Trade Thousands Of Global Markets
Demo account, mobile app and multi-platform access
IG
Visit Site
Empfohlener Broker
Multi Asset Platform
The hRPC treatment has been granted orphan drug status in both the US and Europe with the US Food & Drug Administration (FDA) giving it fast-track status, which bodes well for the treatment.
ReNeuron share price
ReNeuron shares today surged 10.2% to trade at 99p having ended Wednesday’s session trading at 89.8p.
People who read this also read:
- Here are our latest trending stories
- Trade shares CFDs with Pepperstone
- Here are the 7 best shares to buy in 2020